Alan Rigby, Ph.D.

Dr. Alan Rigby is president and founding chief executive officer of a stealth, biotech company focused on new therapies for oncology and neurodegeneration. Alan is an experienced oncology focused, biotech founder / leader focused on company creation, ideation and strategic growth through capital raises, non-dilutive collaborative partnerships and value enhancing asset acquisitions with more than 25 years of academic and industry experience.

As a mission ‘driven’, patient-centric leader, he has focused on impacting patients’ lives through an unwavering commitment to build, focus and accelerate the advancement of innovative first-in-human / first-in-class therapies from conceptualization to clinical advancement. This ‘fast-to-data’, multi-omic data driven approach has resulted in the advancement of several differentiated oncology assets that thoughtfully integrate patient genetics to drive deeper, more meaningful responses. Alan is a passionate team / relationship builder, focused on creating a culture of empowerment through strategic governance, organizational focus, and strong communication.

Prior to his time building and leading biotech companies, Alan was the principal investigator (PI) of an NIH funded, independent academic laboratory at Harvard Medical School. Alan holds an Honors BSc. in Biochemistry from the University of Western Ontario in London, Ontario, Canada and a Ph.D. in Biochemistry from the same University.